{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:07:05Z","timestamp":1788869225052,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T00:00:00Z","timestamp":1426550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.eplepsyres.2015.03.005","type":"journal-article","created":{"date-parts":[[2015,3,31]],"date-time":"2015-03-31T07:51:04Z","timestamp":1427788264000},"page":"76-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies"],"prefix":"10.1016","volume":"113","author":[{"given":"Antonio","family":"Laurenza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0005","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.seizure.2005.12.009","article-title":"Antiepileptic drugs and liver disease","volume":"15","author":"Ahmed","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0010","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.gcb.2010.04.015","article-title":"Back to basics for idiosyncratic drug-induced liver injury: dose and metabolism make the poison","volume":"34","author":"Ballet","year":"2010","journal-title":"Gastroenterol. Clin. Biol."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0015","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jhep.2010.11.006","article-title":"Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver","volume":"54","author":"Begriche","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0020","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.yebeh.2008.01.003","article-title":"Modern management of epilepsy: a practical approach","volume":"12","author":"Elger","year":"2008","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/tx034170b","article-title":"Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development","volume":"17","author":"Evans","year":"2004","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0030","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0035","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","article-title":"Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)","volume":"46","author":"Fisher","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0040","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0050","series-title":"Summary of Product Characteristics","author":"FYCOMPA (perampanel)","year":"2012"},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0055","series-title":"Product Monograph","author":"FYCOMPA (perampanel)","year":"2013"},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0060","series-title":"US Prescribing Information","author":"FYCOMPA (perampanel)","year":"2014"},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0065","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0070","first-page":"14","article-title":"Effect of antiepileptic drugs on liver enzymes","volume":"2","author":"Hussein","year":"2013","journal-title":"Beni-Suef. Univ. J. Basic Appl. Sci."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0075","series-title":"Epilepsy Across the Spectrum: Promoting Health and Understanding","first-page":"1","author":"Institute of Medicine of the National Academies","year":"2012"},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0080","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1528-1167.2012.03648.x","article-title":"Perampanel, a selective, noncompetitive \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307","volume":"54","author":"Krauss","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0085","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0090","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/hep.23317","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events","volume":"51","author":"Lammert","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0095","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJM199510263331706","article-title":"Drug-induced hepatotoxicity","volume":"333","author":"Lee","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0100","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1124\/dmd.109.027797","article-title":"A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding","volume":"37","author":"Nakayama","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0105","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1056\/NEJM200004273421707","article-title":"Evaluation of abnormal liver-enzyme results in asymptomatic patients","volume":"342","author":"Pratt","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14656566.2013.754883","article-title":"Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures","volume":"14","author":"Rektor","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0115","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/NDT.S30129","article-title":"Profile of perampanel and its potential in the treatment of partial onset seizures","volume":"9","author":"Rheims","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12100","article-title":"Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist","volume":"127","author":"Rogawski","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0125","first-page":"55","article-title":"Prediction of a new drug's potential to cause idiosyncratic reactions","volume":"4","author":"Uetrecht","year":"2001","journal-title":"Curr. Opin. Drug Discovery Dev."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0130","series-title":"Drug-Induced Liver Injury: Premarketing Clinical Evaluation","author":"US Food and Drug Administration Guidance for Industry","year":"2009"},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0135","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0140","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/clinchem\/44.5.1085","article-title":"Standards of laboratory practice: antiepileptic drug monitoring. National Academy of Clinical Biochemistry","volume":"44","author":"Warner","year":"1998","journal-title":"Clin. Chem."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0145","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/11586600-000000000-00000","article-title":"Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery","volume":"34","author":"Watkins","year":"2011","journal-title":"Drug Saf."},{"key":"10.1016\/j.eplepsyres.2015.03.005_bib0150","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","article-title":"Idiosyncratic adverse reactions to antiepileptic drugs","volume":"48","author":"Zaccara","year":"2007","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121115000534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121115000534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:32:56Z","timestamp":1760275976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121115000534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":30,"alternative-id":["S0920121115000534"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.03.005","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}